MANK
COM:MANKINDPHARMA
Mankind Pharma
- Stock
Last Close
2,574.40
21/11 10:00
Market Cap
848.24B
Beta: -
Volume Today
275.52K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Mar '20 | Mar '21 | Mar '22 | Mar '23 | ||
|---|---|---|---|---|---|
average inventory | 10.41B - | 14.72B 41.35% | 16.45B 11.73% | ||
average payables | 7.06B - | 8.72B 23.46% | 10.42B 19.57% | ||
average receivables | 5.20B - | ||||
book value per share | 87.00 - | 117.88 35.48% | 153.65 30.35% | 185.61 20.80% | |
capex per share | -5.69 - | -7.80 37.00% | -58.55 651.01% | -20.77 64.53% | |
capex to depreciation | -2.30 - | -2.63 14.07% | -14.08 436.24% | -2.55 81.86% | |
capex to operating cash flow | -0.21 - | -0.27 28.86% | -2.55 828.58% | -0.47 81.72% | |
capex to revenue | -0.04 - | -0.05 29.30% | -0.30 499.76% | -0.10 68.43% | |
cash per share | 27.07 - | 50.04 84.86% | 31.94 36.18% | 38.16 19.49% | |
days of inventory on hand | 170.63 - | 236.71 38.73% | 260.12 9.89% | 104.22 59.93% | |
days payables outstanding | 141.40 - | 133.40 5.66% | 159.06 19.24% | 68.72 56.79% | |
days sales outstanding | 25.57 - | ||||
debt to assets | 0.03 - | 0.04 46.38% | 0.10 152.73% | 0.02 82.18% | |
debt to equity | 0.04 - | 0.05 35.72% | 0.14 178.31% | 0.02 84.34% | |
dividend yield | 0.01 - | ||||
earnings yield | 0.02 - | 0.02 22.43% | 0.03 12.37% | 0.02 11.78% | |
enterprise value | 568.81B - | 570.49B 0.30% | 575.46B 0.87% | 568.41B 1.23% | |
enterprise value over ebitda | 35.27 - | 31.97 9.35% | 27.53 13.87% | 29.24 6.20% | |
ev to operating cash flow | 53.17 - | 50.16 5.66% | 62.57 24.72% | 31.85 49.09% | |
ev to sales | 9.70 - | 9.18 5.34% | 7.40 19.44% | 6.50 12.09% | |
free cash flow per share | 21.01 - | 20.59 2.00% | -35.59 272.83% | 23.78 166.81% | |
free cash flow yield | 0.01 - | 0.01 2.00% | -0.03 272.83% | 0.02 166.81% | |
graham net net | 3.30 - | 27.12 721.89% | -16.78 161.85% | 17.12 202.04% | |
graham number | 227.18 - | 292.59 28.79% | 354.11 21.03% | 365.56 3.23% | |
income quality | 0.74 - | 0.67 9.64% | 0.47 30.71% | 1.39 198.88% | |
intangibles to total assets | 0.01 - | 0.01 32.72% | 0.21 3,266.60% | 0.19 10.62% | |
interest coverage | 69.05 - | 86.28 24.95% | 34.48 60.04% | 38.53 11.76% | |
interest debt per share | 3.81 - | 6.49 70.13% | 23.19 257.30% | 5.17 77.70% | |
inventory turnover | 2.14 - | 1.54 27.92% | 1.40 9.00% | 3.50 149.59% | |
invested capital | 0.04 - | 0.05 35.72% | 0.14 178.31% | 0.02 84.34% | |
market cap | 569.76B - | 569.76B 0% | 569.76B 0% | 569.76B 0% | |
net current asset value | 14.21B - | 23.97B 68.74% | 15.75B 34.27% | 22.61B 43.53% | |
net debt to ebitda | -0.06 - | 0.04 169.77% | 0.27 563.01% | -0.07 125.34% | |
net income per share | 26.36 - | 32.28 22.43% | 36.27 12.37% | 32.00 11.78% | |
operating cash flow per share | 26.70 - | 28.39 6.31% | 22.96 19.12% | 44.55 94.02% | |
payables turnover | 2.58 - | 2.74 6.00% | 2.29 16.13% | 5.31 131.44% | |
receivables turnover | 14.28 - | ||||
research and ddevelopement to revenue | 0.02 - | ||||
return on tangible assets | 0.21 - | 0.20 2.83% | 0.20 1.88% | 0.16 19.17% | |
revenue per share | 146.42 - | 155.13 5.95% | 194.25 25.22% | 218.25 12.35% | |
roe | 0.30 - | 0.27 9.63% | 0.24 13.80% | 0.17 26.96% | |
roic | 0.31 - | 0.26 16.59% | 0.20 21.47% | 0.17 17.32% | |
sales general and administrative to revenue | 0.01 - | 0.01 33.42% | 0.02 32.98% | ||
shareholders equity per share | 87.00 - | 117.88 35.48% | 153.65 30.35% | 185.61 20.80% | |
stock based compensation to revenue | |||||
tangible asset value | 36.25B - | 48.24B 33.06% | 44.22B 8.33% | 58.50B 32.31% | |
tangible book value per share | 90.50 - | 120.41 33.06% | 110.38 8.33% | 146.04 32.31% | |
working capital | 15.64B - | 25.53B 63.29% | 17.83B 30.15% | 24.65B 38.21% |
All numbers in (except ratios and percentages)